KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Accumulated Expenses (2012 - 2015)

AbbVie (ABBV) reported Accumulated Expenses of $411.0 million for Q4 2015, down 49.94% year-over-year from $821.0 million in Q4 2014, and down 49.94% on a QoQ basis from $821.0 million in Q4 2014.

AbbVie (ABBV) has 4 years of Accumulated Expenses data on file, last reported at $411.0 million in Q4 2015.

  • Quarterly Accumulated Expenses fell 49.94% year-over-year to $411.0 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $411.0 million (down 49.94% YoY) and the FY2015 annual result came in at $411.0 million, down 49.94% from the prior year.
  • Accumulated Expenses retreated to $411.0 million in Q4 2015 per ABBV's latest filing, from $821.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $821.0 million in Q4 2014 and bottomed at $411.0 million in Q4 2015.
  • The 4-year median for Accumulated Expenses is $572.0 million (2012), against an average of $594.0 million.
  • The widest annual swing landed in 2014, when Accumulated Expenses jumped 32.21%; it then tumbled 49.94% in 2015.
  • Tracing ABBV's Accumulated Expenses over 4 years: stood at $523.0 million in 2012, then advanced by 18.74% to $621.0 million in 2013, then jumped by 32.21% to $821.0 million in 2014, then plunged by 49.94% to $411.0 million in 2015.
  • Per Business Quant, the three latest ABBV Accumulated Expenses figures stand at $411.0 million (Q4 2015), $821.0 million (Q4 2014), and $621.0 million (Q4 2013).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2015 411.00 Mn
Dec 31, 2014 821.00 Mn
Dec 31, 2013 621.00 Mn
Dec 31, 2012 523.00 Mn